Sandoz Group AG - Registered Shares SDZ

SWX: SDZ | ISIN: CH1243598427   25/02/2026
72,42 CHF (+10,33%)
(+10,33%)   25/02/2026
Grafiek Sandoz Group AG - Registered Shares Grafiek Sandoz Group AG - Registered Shares
woensdag 25 februari 2026, 07:00
Jaarresultaten

Sandoz Group AG - Registered Shares in het nieuws

12 augustus 2025 · Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations · Persbericht

7 augustus 2025 · Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter · Persbericht

30 juli 2025 · Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France · Persbericht

1 juli 2025 · Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reach · Persbericht

2 juni 2025 · Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1] · Persbericht

21 mei 2025 · Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars · Persbericht

30 april 2025 · Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed · Persbericht

29 april 2025 · Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications · Persbericht

15 april 2025 · Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG · Persbericht

14 april 2025 · [Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US · Persbericht

Mijn selecties